Pfizer Inc. $PFE Shares Sold by Principle Wealth Partners LLC

Principle Wealth Partners LLC reduced its holdings in shares of Pfizer Inc. (NYSE:PFE) by 5.9% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 163,543 shares of the biopharmaceutical company’s stock after selling 10,333 shares during the quarter. Principle Wealth Partners LLC’s holdings in Pfizer were worth $3,964,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also made changes to their positions in the company. GKV Capital Management Co. Inc. acquired a new position in shares of Pfizer during the 1st quarter worth about $27,000. Bayforest Capital Ltd acquired a new position in shares of Pfizer during the 1st quarter worth about $28,000. North Capital Inc. acquired a new position in shares of Pfizer during the 1st quarter worth about $28,000. Harbor Asset Planning Inc. acquired a new position in shares of Pfizer during the 2nd quarter worth about $29,000. Finally, WPG Advisers LLC acquired a new position in shares of Pfizer during the 1st quarter worth about $35,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

PFE has been the subject of several analyst reports. Wall Street Zen cut Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th. Bank of America boosted their target price on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a report on Friday, October 3rd. Morgan Stanley reduced their target price on Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a report on Friday, October 10th. Finally, Citigroup boosted their target price on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $28.13.

Pfizer Stock Down 0.5%

PFE opened at $24.72 on Thursday. The business has a 50 day moving average price of $24.88 and a two-hundred day moving average price of $24.13. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The company has a market cap of $140.52 billion, a PE ratio of 13.15, a P/E/G ratio of 0.82 and a beta of 0.55. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $29.17.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.58 by $0.20. The firm had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm’s revenue was up 10.3% compared to the same quarter last year. During the same period in the prior year, the business earned $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, November 7th. This represents a $1.72 annualized dividend and a yield of 7.0%. Pfizer’s dividend payout ratio is currently 91.49%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.